Can seniors get weight loss drugs for $50 through Medicare? What the GLP-1 Bridge covers, who qualifies, and why long-term access remains uncertain.

Key Highlights

  • Medicare has long been legally barred from covering weight loss drugs, leaving millions of seniors paying over $1,000 per month out of pocket.
  • The Trump administration struck a deal with drugmakers to bring that cost down to $50 per month for eligible seniors.
  • Health insurers refused to participate, forcing the government to fund the program directly.
  • A short-term bridge program launches July 1, 2026, but carries meaningful gaps in coverage and eligibility.
  • The longer-term solution remains uncertain, dependent on voluntary insurer participation that has so far not materialised.

The Drug That Changed Everything

Over the past few years, a new class of medications known as GLP-1s has fundamentally shifted how medicine treats obesity. Drugs like Wegovy, made by Novo Nordisk (NYSE:NVO), and Zepbound, made by Eli Lilly (NYSE:LLY), have demonstrated significant and sustained weight loss in clinical trials, with additional benefits for heart disease and diabetes. Demand has been extraordinary.

The problem for America's 67 million Medicare beneficiaries, most of whom are aged 65 and above, is straightforward: these drugs are extraordinarily expensive, and Medicare has historically been legally prohibited from covering them for weight loss.

Without insurance coverage, a single month's supply of Wegovy or Zepbound can cost between $900 and $1,200. For seniors living on fixed incomes, that number is effectively prohibitive.

The scale of the unmet need is significant. Approximately 48% of people covered by Medicare are obese, while 38% of Americans on Medicaid and the Children's Health Insurance Program have a body mass index of 30 or higher. For Eli Lilly and Novo Nordisk, Medicare represents a growth opportunity of considerable strategic importance. Novo Nordisk CEO Mike Doustdar told investors in February that Medicare is a patient population the company would very much like to serve with its GLP-1 products. Eli Lilly CFO Lucas Montarce echoed that view on a February earnings call, noting that the company is strongly positive about the opportunity to bring anti-obesity medications to Medicare patients. Montarce also indicated that between 10% and 20% of patients currently purchasing Lilly medications through LillyDirect, the company's direct cash-pay portal, are expected to transition into the Medicare coverage framework once access opens.

What the Government Promised

In November 2025, the Trump administration announced it had negotiated directly with Eli Lilly and Novo Nordisk to reduce GLP-1 prices for Medicare and Medicaid beneficiaries. In exchange for broader government access, drugmakers agreed to sell these medications to the program at approximately $245 per month. The government, in turn, promised seniors they would pay only $50 per month out of pocket.

To make this work within existing law, the administration created a demonstration program called the BALANCE Model. Demonstration programs are a mechanism that allows Centers for Medicare and Medicaid Services (CMS), the federal agency overseeing Medicare and Medicaid, to test coverage of treatments that would otherwise be legally excluded, on the basis that they may improve health outcomes or reduce long-term costs.

The plan was for private health insurers that manage Medicare drug coverage, known as Part D plans, to administer this benefit and carry the financial risk of covering the gap between the $245 drug cost and the $50 patient copay. BALANCE was designed as a voluntary program, meaning insurers could choose whether or not to participate.

They chose not to.

Why Insurers Walked Away

Health insurers operate on margins that are sensitive to large, uncertain cost exposures. GLP-1 medications are expensive, demand is high, and usage, once started, tends to be long-term. Agreeing to cover millions of seniors at a subsidised rate, on a voluntary basis, with no guaranteed return, was a financial proposition most Part D plan sponsors declined to accept.

The resistance has now become concrete and named. CVS Health (NYSE: CVS), through its Aetna insurance division, confirmed to Bloomberg that it will not join the program. UnitedHealth Group (NYSE: UNH) stopped short of a formal refusal but struck a cautious tone. Bobby Hunter, chief executive of UnitedHealthcare's government programs, described "notable challenges and outstanding questions" around the program on the company's earnings call on April 22, 2026, adding that the organisation is still working through the process internally and looks forward to continuing dialogue with CMS.

The combined weight of these positions is arithmetically significant. RBC Capital Markets analyst Trung Huynh observed in a research note that with CVS out and UnitedHealth non-committal beyond the Bridge program, the 80% participation threshold becomes difficult to reach.

This created a structural problem. CMS had set a condition: if fewer than 80% of Part D plan sponsors agreed to participate, the full BALANCE Model would not launch in Medicare in January 2027. With widespread insurer refusal, that threshold is now at serious risk of not being met.

Rather than abandon the commitment to seniors entirely, CMS redesigned the short-term component of the program. Instead of routing the benefit through private insurers, the federal government will manage everything directly, using a centralised contractor to handle approvals, claims, and pharmacy payments. Insurers are removed from the equation altogether.

What Seniors Can Actually Expect

A program called the Medicare GLP-1 Bridge will open on July 1, 2026, and run through December 31, 2027. Eligible seniors will pay $50 per month for either Wegovy or Zepbound, prescribed specifically for weight management.

To qualify, a senior must be enrolled in a Medicare Part D drug plan and meet one of two clinical criteria: a BMI of 35 or above, or a BMI of 27 or above alongside qualifying health conditions such as cardiovascular disease or prediabetes. A doctor must request prior authorisation through a central CMS system before a prescription can be filled.

However, several important limitations apply.

The $50 monthly payment does not count toward the standard Medicare Part D out-of-pocket spending cap of $2,100. That means seniors who are already paying for other medications under Part D will not receive any credit toward their annual cap from GLP-1 spending under the Bridge. The two cost-tracking systems run separately.

For low-income seniors who rely on the Low-Income Subsidy, a Medicare program that reduces their drug costs to very small amounts, that protection does not apply here. They will pay the same $50 as everyone else, which for some may still be unaffordable.

Looking further ahead, access beyond 2027 is not guaranteed. If the broader BALANCE Model fails to launch in Medicare due to insufficient insurer participation, seniors who began treatment under the Bridge may face a gap in coverage, or be required to switch insurance plans to maintain access.

What This Means Going Forward

The episode reveals a recurring tension in American healthcare policy. The government can negotiate drug prices and make coverage promises, but if the private sector entities required to deliver that coverage decline to participate, the system strains. CMS has, for now, stepped in as a direct payer. Whether that is a durable arrangement or a temporary patch depends on whether health insurers can eventually be brought into the longer-term program on terms they find acceptable.

Markets responded immediately. Shares of Eli Lilly closed approximately 1.8% lower on April 22, 2026, while Novo Nordisk's US-listed shares fell around 2.6% after insurer resistance became public following the Bloomberg report and UnitedHealth's earnings call. However, not all analysts viewed the selloff as warranted. BMO Capital Markets analyst Evan David Seigerman told investors that the share price declines may be overdone, noting that nothing in UnitedHealth's public commentary suggested a retreat from GLP-1 coverage broadly or an unwillingness to engage in outcomes-based reimbursement arrangements going forward.

For seniors with obesity-related conditions, the July 2026 launch is meaningful progress after years of exclusion. But the architecture surrounding that progress remains incomplete, and the commercial stakes for the two dominant GLP-1 manufacturers are now directly tied to whether Washington and the insurance industry can reach workable terms.